Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGX-001 first-in-human study in p47phox-deficient chronic granulomatous disease
2025-524423-50-00Phase 2Authorised
- Sponsor
- Somagenetix
- Start
- Oct 2026
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of SGX-001 in chronic granulomatous disease (CGD), sponsored by Somagenetix. Primary endpoints: Safety through Month 12 and Treatment response at Month 12. Planned start Oct 2026; status: authorised.
02
Drugs
SGX-001
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on 2025-524423-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524423-50-00.